Study of VIR-2218 in Healthy Volunteers and Patients With Chronic Hepatitis B
Status:
Completed
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 study in which healthy volunteers and subjects with chronic HBV infection
will receive VIR-2218 or placebo and will be assessed for safety, tolerability,
pharmacokinetics, and antiviral activity (only in subjects with chronic HBV).